Interestingly, the expression status of MAGEC2 is strongly associated with the relapse-free survival of basal-like breast cancer patients and has little or no effect on the relapse-free survival of ER positive or ER negative breast cancer subtypes (Figure S5). Here, MAGEC2 is linked to breast carcinoma.